N -(2-{3-[3,5-bis(trifluoromethyl)phenyl]ureido}ethyl)-glycyrrhetinamide (6b): A novel anticancer glycyrrhetinic acid derivative that targets the proteasome and displays anti-kinase activity

Journal of Medicinal Chemistry

Volumn 54, Issue 19, 2011, Pages 6501-6513

  Lallemand, Benjamin ^a   Chaix, Fabien ^c   Bury, Marina ^b   Bruyère, Céline ^b   Ghostin, Jean ^c   Becker, Jean Paul ^a   Delporte, Cédric ^a   Gelbcke, Michel ^a   Mathieu, Véronique ^b   Dubois, Jacques ^a   Prévost, Martine ^a   Jabin, Ivan ^c   Kiss, Robert ^b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Laboratoire de Toxicologie   (Belgium)

^c Laboratoire de Chimie Organique   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

(THIO)UREIDO GLYCYRRHETINAMIDE DERIVATIVE; 18 BETA GLYCYRRHETINAMIDE DERIVATIVE; 18 BETA GLYCYRRHETINDIAMIDE DERIVATIVE; 18 BETA GLYCYRRHETINIC ACID; ACTIN; ANTINEOPLASTIC AGENT; GLYCYRRHETINIC ACID DERIVATIVE; N (2 AMINOETHYL)GLYCYRRHETINAMIDE; N [2 [3 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]UREIDO]ETHYL]GLYCYRRHETINAMIDE; PROTEASOME; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSKELETON; CYTOSTASIS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN DEGRADATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCYRRHETINIC ACID; HUMANS; MICE; MODELS, MOLECULAR; PHENYLUREA COMPOUNDS; PPAR GAMMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053926550     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200285z     Document Type: Article

References (90)

1. Obolentseva, G. V.; Litvinenko, V. I.; Ammosov, A. S.; Popova, T. P.; Sampiev, A. M. Pharmacological and therapeutic properties of licorice preparations Pharm. Chem. J. 1999, 33, 427-434 (Pubitemid 30213895)
2. Abe, H.; Ohya, N.; Yamamoto, K. F.; Shibuya, T.; Arichi, S.; Odashima, S. Effects of glycyrrhizin and glycyrrhetinic acid on growth and melanogenesis in cultured B16 melanoma cells Eur. J. Cancer Clin. Oncol. 1987, 23, 1549-1555
3. Okamoto, H.; Yoshida, D.; Mizusaki, S. Inhibition of 12-O- tetradecanoylphorbol-13-acetate-induced induction in Epstein-Barr virus early antigen in Raji cells Cancer Lett. 1983, 19, 47-53 (Pubitemid 13100911)
4. Hibasami, H.; Iwase, H.; Yoshioka, K.; Takahashi, H. Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells Int. J. Mol. Med. 2006, 17, 215-219
5. Isbrucker, R. A.; Burdock, G. A. Risk and safety assessment on the consumption of licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin Regul. Toxicol. Pharmacol. 2006, 46, 167-192 (Pubitemid 44692903)
6. Zhang, M.-Z.; Xu, J.; Yao, B.; Yin, H.; Cai, Q.; Shrubsole, M. J.; Chen, X.; Kon, V.; Zheng, W.; Pozzi, A.; Harris, R. C. Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans J. Clin. Invest. 2009, 119, 876-885
7. Satomi, Y.; Nishino, H.; Shibata, S. Glycyrrhetinic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2 Anticancer Res. 2005, 25, 4043-4047 (Pubitemid 41665183)
8. Hawthorne, S.; Gallagher, S. Effects of glycyrrhetinic acid and liquorice extract on cell proliferation and prostate-specific antigen secretion in LNCaP prostate cancer cells J. Pharm. Pharmacol. 2008, 60, 661-666 (Pubitemid 351589055)
9. Lee, C. S.; Yang, J. C.; Kim, Y. J.; Jang, E. R.; Kim, W.; Myung, S. C. 18beta-glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines Eur. J. Pharmacol. 2010, 649, 354-361
10. Salvi, M.; Fiore, C.; Armanini, D.; Toninello, A. Glycyrrhetinic acid-induced permeability transition in rat liver mitochondria Biochem. Pharmacol. 2003, 66, 2375-2379 (Pubitemid 37456745)
11. Lee, C. S.; Kim, Y. J.; Lee, M. S.; Han, E. S.; Lee, S. J. 18beta-Glycyrrhetinic acid induces apoptotic cell death in SiHa cells and exhibits a synergistic effect against antibiotic anti-cancer drug toxicity Life Sci. 2008, 83, 481-489
12. Schwarz, S.; Csuk, R. Synthesis and antitumour activity of glycyrrhetinic acid derivatives Bioorg. Med. Chem. 2010, 18, 7458-7474
13. Anuchapreeda, S.; Leechanachai, P.; Smith, M. M.; Ambudkar, S. V.; Limtrakul, P. N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells Biochem. Pharmacol. 2002, 64, 573-582
14. Mayur, Y. C.; Peters, G. J.; Prasad, V. V.; Lemo, C.; Sathish, N. K. Design of new drug molecules to be used in reversing multidrug resistance in cancer cells Curr. Cancer Drug Targets 2009, 9, 298-306
15. Jutooru, I.; Chadalapaka, G.; Chintharlapalli, S.; Papineni, S.; Safe, S. Induction of apoptosis and nonsteroidal anti-inflammatory drug-activated gene 1 in pancreatic cancer cells by a glycyrrhetinic acid derivative Mol. Carcinog. 2009, 48, 692-702
16. Chung, T. H.; Wang, S. M.; Chang, Y. C.; Chen, Y. L.; Wu, J. C. 18beta-glycyrrhetinic acid promotes src interaction with connexin43 in rat cardiomyocytes J. Cell Biochem. 2007, 100, 653-664
17. Kawakami, Z.; Ikarashi, Y.; Kase, Y. Glycyrrhizin and its metabolite 18beta-glycyrhetinic acid in glycyrrhiza, a constituent herb of yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes Eur. J. Pharmacol. 2010, 626, 154-158
18. Pang, X.; Zhang, L.; Wu, Y.; Lin, L.; Li, J.; Qu, W.; Safe, S.; Liu, M. Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate (CDODA-Me), a derivative of glycyrrhetinic acid, functions as a potent angiogenesis inhibitor J. Pharmacol. Exp. Ther. 2010, 335, 172-179
19. Kao, T.; Shyu, M. H.; Yen, G. C. Glycyrrhizic acid and 18beta-glycyrrhetinic acid inhibit inflammation via PI3K/Akt/GSK3beta signaling and glucocorticoid receptor activation J. Agric. Food Chem. 2010, 58, 8623-8629
20. Huang, L.; Yu, D.; Ho, P.; Qian, K.; Lee, K. H.; Chen, C. H. Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives Bioorg. Med. Chem. 2008, 16, 6696-6701
21. Chintharlapalli, S.; Papineni, S.; Jutooru, I.; McAlees, A.; Safe, S. Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor gamma agonists in colon cancer cells Mol. Cancer Ther. 2007, 6, 1588-1598 (Pubitemid 46954026)
22. Chintharlapalli, S.; Papineni, S.; Konopleva, M.; Andreef, M.; Samudio, I.; Safe, S. 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways Mol. Pharmacol. 2005, 68, 119-128 (Pubitemid 41002950)
23. Papineni, S.; Chintharlapalli, S.; Safe, S. Methyl 2-cyano-3,11-dioxo- 18beta -olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor-gamma agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells Mol. Pharmacol. 2008, 73, 553-565 (Pubitemid 351159224)
24. Chadalapaka, G.; Jutooru, I.; McAlees, A.; Stefanac, T.; Safe, S. Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives Bioorg. Med. Chem. Lett. 2008, 18, 2633-2639 (Pubitemid 351503883)
25. Michalik, L.; Wahli, W. PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008, ID 134059, doi: 10.1155/2008/134059.
26. Bundscherer, A.; Reichle, A.; Hafner, C.; Meyer, S.; Vogt, T. Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonists Anticancer Agents Med. Chem. 2009, 9, 816-821
27. He, X.; Yu, S.; Dong, Y. Y.; Yan, F.; Chen, L. Preparation and properties of a novel thermo-responsive poly(N-isopropylacrylamide) hydrogel containing glycyrrhetinic acid J. Mater. Sci. 2009, 44, 4078-4086
28. Tatsuzaki, J.; Taniguchi, M.; Bastow, K. F.; Nakagawa-Goto, K.; Morris-Natschke, S. L.; Itokawa, H.; Baba, K.; Lee, K.-H. Anti-tumor agents: Novel glycyrrhetinic acid-dehydrozingerone conjugates as cytotoxic agents Bioorg. Med. Chem. 2007, 15, 6193-6199 (Pubitemid 47088956)
29. Fukuoka, S.; Kida, T.; Nakajima, Y.; Tsumagari, T.; Watanabe, W.; Inaba, Y.; Mori, A.; Matsumura, T.; Nakano, Y.; Takeshita, K. Thermo-responsive extraction of cadmium(II) ion with TPEN-NIPA gel. Effect of the number of polymerizable double bond toward gel formation and the extracting behavior Tetrahedron 2010, 66, 1721-1727
30. Joseph, B.; Darro, F.; Béliard, A.; Lesur, B.; Collignon, F.; Decaestecker, C.; Frydman, A.; Guillaumet, G.; Kiss, R. 3-aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo anti-tumor effects with emphasis on a new therapeutical target connected with cell migration J. Med. Chem. 2002, 45, 2543-2555 (Pubitemid 34595224)
31. Ozap-Yaman, S.; de Hoog, P.; Amadei, G.; Pitié, M.; Gamez, P.; Dewelle, J.; Mijatovic, T.; Meunier, B.; Kiss, R.; Reedijk, J. Platined copper (3-clip-phen) complexes as effective DNA-cleaving and cytotoxic agents Chem.-Eur. J. 2008, 14, 3418-3426
32. Lamoral-Theys, D.; Andolfi, A.; Van Goietsenoven, G.; Cimmino, A.; Le Calvé, B.; Wauthoz, N.; Mégalizzi, V.; Gras, T.; Bruyère, C.; Dubois, J.; Mathieu, V.; Kornienko, A.; Kiss, R.; Evidente, A. Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: An investigation of structure-activity relationship and mechanistic insight J. Med. Chem. 2009, 52, 6244-6256
33. Ingrassia, L.; Lefranc, F.; Dewelle, J.; Pottier, L.; Mathieu, V.; Spiegl-Kreinecker, S.; Sauvage, S.; El Yazidi, M.; Dehoux, M.; Berger, W.; Van Quaquebeke, E.; Kiss, R. Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents J. Med. Chem. 2009, 52, 1100-1114
34. Branle, F.; Lefranc, F.; Camby, I.; Jeuken, J.; Geurts-Moespot, A.; Sprenger, S.; Sweep, F.; Kiss, R.; Salmon, I. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy Cancer 2002, 95, 641-655 (Pubitemid 34810191)
35. Mathieu, A.; Remmelink, M.; D'Haene, N.; Penant, S.; Gaussin, J. F.; Van Ginckel, R.; Darro, F.; Kiss, R.; Salmon, I. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice Cancer 2004, 101, 1908-1918
36. Mijatovic, T.; Mathieu, V.; Gaussin, J. F.; De Nève, N.; Ribaucour, F.; Van Quaquebeke, E.; Dumont, P.; Darro, F.; Kiss, R. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers Neoplasia 2006, 5, 402-412 (Pubitemid 43830747)
37. Mathieu, V.; Pirker, C.; Martin de Lassalle, E.; Vernier, M.; Mijatovic, T.; De Neve, N.; Gaussin, J. F.; Dehoux, M.; Lefranc, F.; Berger, W.; Kiss, R. The sodium pump alpha-1 subunit: a disease progression-related target for metastatic melanoma treatment J. Cell Mol. Med. 2009, 13, 3960-3972
38. Dumont, P.; Ingrassia, L.; Rouzeau, S.; Ribaucour, F.; Thomas, S.; Roland, I.; Darro, F.; Lefranc, F.; Kiss, R. The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts Neoplasia 2007, 9, 766-776 (Pubitemid 47523238)
39. Gerber, D. E.; Minna, J. D. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time Cancer Cell 2010, 18, 548-551
40. Qiu, Y.; Kung, H. J. Signaling network of the Btk family kinases Oncogene 2000, 19, 5651-5661
41. Dopeso, H.; Mateo-Lozano, S.; Mazzolini, R.; Rodrigues, P.; Lagares-Tena, L.; Ceron, J.; Romero, J.; Esteves, M.; Landolfi, S.; Hernandez-Losa, J.; Castano, J.; Wilson, A. J.; Ramon y Cajal, S.; Mariadason, J. M.; Schwartz, S., Jr.; Arango, D. The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis Cancer Res. 2009, 69, 7430-7438
42. Herath, N. I.; Boyd, A. W. The role of Eph receptors and ephrin ligands in colorectal cancer Int. J. Cancer 2010, 126, 2003-2011
43. Smith, J. A.; Samayawardhena, L. A.; Craig, A. W. Fps/Fes protein-tyrosine kinase regulats mast cell adhesion and migration dowstrean of kit and beta1 integrin receptors Cell Signal 2010, 22, 427-436
44. Saito, Y. D.; Jensen, A. R.; Salgia, R.; Posadas, E. M. Fyn: a novel molecular target in cancer Cancer 2010, 116, 1629-1637
45. Katoh, M. FGFR2 abnormalities underlies a spectrum of bone, skin, and cancer pathologies J. Invest. Dermatol. 2009, 129, 1861-1867
46. Scartozzi, M.; Bianconi, M.; Maccaroni, E.; Giamperi, R.; Beradi, R.; Cascinu, S. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer Curr. Opin. Mol. Ther. 2010, 12, 361-371
47. Cockburn, J. G.; Richardson, D. S.; Gujral, T. S.; Mulligan, L. M. RET-mediated cell adhesion and migration require multiple integrin subunits J. Clin. Endocrinol. Metab. 2010, 95, E342-E346
48. Lee, B. C.; Lee, T. H.; Zagozdzon, R.; Avraham, S.; Usheva, A.; Avraham, H. K. Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration Cancer Res. 2005, 65, 2840-2845 (Pubitemid 40490087)
49. Coniglio, S. J.; Zavarella, S.; Symons, M. H. Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms Mol. Cell. Biol. 2008, 28, 4162-4172 (Pubitemid 351812999)
50. Lee, D. H.; Goldberg, A. L. Proteasome inhibitors: valuable new tools for cell biologists Trends Cell Biol. 1998, 8, 397-403 (Pubitemid 28458705)
51. Hines, J.; Groll, M.; Fahnestock, M.; Crews, C. M. Proteasome Inhibition by Fellutamide B Induces Nerve Growth Factor Synthesis Chem. Biol. (Cambridge, MA, U. S.) 2008, 15, 501-512 (Pubitemid 351658945)
52. de Bettignies, G.; Coux, O. Proteasome inhibitors: Dozens of molecules and still counting Biochimie 2010, 92, 1530-1545
53. Blackburn, C.; Gigstad, K. M.; Hales, P.; Garcia, K.; Jones, M.; Bruzzese, F. J.; Barrett, C.; Liu, J. X.; Soucy, T. A.; Sappal, D. S.; Bump, N.; Olhava, E. J.; Fleming, P.; Dick, L. R.; Tsu, C.; Sintchak, M. D.; Blank, J. L. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta 5-subunit Biochem. J. 2010, 430, 461-476
54. Geurink, P. P.; Liu, N.; Spaans, M. P.; Downey, S. L.; van den Nieuwendijk, A. M. C. H.; van der Marel, G. A.; Kisselev, A. F.; Florea, B. I.; Overkleeft, H. S. Incorporation of fluorinated phenylalanine generates highly specific inhibitor of proteasome's chymotrypsin-like sites J. Med. Chem. 2010, 53, 2319-2323
55. Furet, P.; Imbach, P.; Noorani, M.; Koeppler, J.; Laumen, K.; Lang, M.; Guagnano, V.; Fuerst, P.; Roesel, J.; Zimmermann, J.; Garcia Echeverria, C. Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design J. Med. Chem. 2004, 47, 4810-4813 (Pubitemid 39238254)
56. Simpson, C. D.; Anyiwe, K.; Schimmer, A. D. Anoikis resistance and tumor metastasis Cancer Lett. 2008, 272, 177-185
57. Savage, P.; Stebbing, J.; Bower, M.; Crook, T. Why does cytotoxic chemotherapy cure only some cancers? Nat. Clin. Pract. Oncol. 2009, 6, 43-52
58. Wilson, T. R.; Johnston, P. G.; Longley, D. B. Anti-apoptotic mechanisms of drug resistance in cancer Curr. Cancer Drug Targets 2009, 9, 307-319
59. Bozec, A.; Peyrade, F.; Fischel, J. L.; Milano, G. Emerging molecular targeted therapies in the treatment of head and neck cancer Expert Opin. Emerg. Drugs 2009, 14, 299-310
60. Han, S.; Roman, J. Targeting apoptotic signaling pathways in human lung cancer. Curr. Cancer Drug Targets 2010, in press.
61. Soengas, M. S.; Lowe, S. W. Apoptosis and melanoma chemoresistance Oncogene 2003, 22, 3138-3151 (Pubitemid 36713766)
62. Wong, H. H.; Lemoine, N. R. Pancreatic cancer: molecular pathogenesis and new therapeutic targets Nat. Rev. Gastroenterol. Hepatol. 2009, 6, 412-422
63. D'Amico, T. A.; Harpole, D. H., Jr. Molecular biology of esophageal cancer Chest Surg. Clin. N. Am. 2000, 10, 451-469 (Pubitemid 30627541)
64. Bruyère, C.; Lonez, C.; Duray, A.; Cludts, S.; Ruysschaert, J. M.; Saussez, S.; Yeaton, P.; Kiss, R.; Mijatovic, T. Considering Temozolomide as a novel potential treatment for oesophageal cancer Cancer 2011, 117, 2004-2016
65. Lefranc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatment of glioblastomas, with a special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis J. Clin. Oncol. 2005, 23, 2411-2422 (Pubitemid 46218735)
66. Landis-Piwowar, K. R.; Milacic, V.; Chen, D.; Yang, H.; Zhao, Y.; Chan, T. H.; Yan, B.; Dou, Q. P. The proteasome as a potential target for novel anticancer drugs and chemosensitizers Drug Resist. Updates 2006, 9, 263-273 (Pubitemid 46357634)
67. Guo, L.; Zhou, Y.; Sun, Y.; Zhang, F. Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer Eur. J. Cancer 2010, 46, 636-641
68. Chen, D.; Dou, Q. P. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention Curr. Protein Pept. Sci. 2010, 11, 459-470
69. Tsukamoto, S.; Yokosawa, H. Targeting the proteasome pathway Expert Opin. Ther. Targets 2009, 13, 605-621
70. Liggett, A.; Crawford, L. J.; Walker, B.; Morris, T. C. M.; Irvine, A. E. Methods for measuring proteasome activity: Current limitations and future developments Leukemia Res. 2010, 34, 1403-1409
71. Lefranc, F.; Facchini, V.; Kiss, R. Pro-autophagic drugs: A novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas Oncologist 2007, 12, 1395-1403
72. Wu, W. K.; Cho, C. H.; Lee, C. W.; Wu, K; Fan, D; Yu, J; Sung, J. J. Proteasome inhibition: a new therapeutic strategy to cancer treatment Cancer Lett. 2010, 293, 15-22
73. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D.-L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma New Engl. J. Med. 2003, 348, 2609-2617 (Pubitemid 36741588)
74. Richardson, P. G.; Briemberg, H.; Jagannath, S.; Wen, P. Y.; Barlogie, B.; Berenson, J.; Singhal, S.; Siegel, D. S.; Irwin, D.; Schuster, M.; Srkalovic, G.; Alexanian, R.; Rajkumar, S. V.; Limentani, S.; Alsina, M.; Orlowski, R. Z.; Najarian, K.; Esseltine, D.; Anderson, K. C.; Amato, A. A. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib J. Clin. Oncol. 2006, 24, 3113-3120 (Pubitemid 46638949)
75. Lonial, S.; Waller, E. K.; Richardson, P. G.; Jagannath, S.; Orlowski, R. Z.; Giver, C. R.; Jaye, D. L.; Francis, D.; Giusti, S.; Torre, C.; Barlogie, B.; Berenson, J. R.; Sunghal, S.; Schenkein, D. P.; Esseltine, D. L. W.; Anderson, J.; Xiao, H.; Heffner, L. T.; Anderson, K. C. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma Blood 2005, 106, 3777-3784 (Pubitemid 41739012)
76. Blanquicett, C.; Roman, J.; Hart, C. M. Thiazolidinediones as anti-cancer agents Cancer Ther. 2008, 6, 25-34
77. He, B. C.; Chen, L.; Zuo, G. W.; Zhang, W.; Bi, Y.; Huang, J.; Wang, Y.; Jiang, W.; Luo, Q.; Shi, Q.; Zhang, B. Q.; Liu, B.; Lei, X.; Luo, J.; Luo, X.; Wagner, E. R.; Kim, S. H.; He, C. J.; Hu, Y.; Shen, J.; Zhou, Q.; Rastegar, F.; Deng, Z. L.; Luu, H. H.; He, T. C.; Haydon, R. C. Synergistic antitumor effect of the activated PPARgamma and retinoid recptors on human osteosarcoma Clin. Cancer Res. 2010, 16, 2235-2245
78. Lee, J. Y.; Kim, J. K.; Cho, M. C.; Shin, S.; Yoon, D. Y.; Heo, Y. S.; Kim, Y. Cytotoxic flavonoids as agonists of peroxysome proliferator-activated receptor gamma on human cervical and prostate cancer cells J. Nat. Prod. 2010, 73, 1261-1265
79. Reka, A. K.; Kurapati, H.; Narala, V. R.; Bommer, G.; Chen, J.; Standiford, T. J.; Keshamouni, V. G. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition Mol. Cancer Res. 2010, 9, 3221-3232
80. Voutsadakis, I. A. Peroxisome proliferator activated receptor-gamma and the ubiquitin-proteasome system in colorectal cancer World J. Gastrointest. Oncol. 2010, 2, 235-241
81. Knight, Z. A.; Lin, H.; Shokat, K. M. Targeting the cancer kinome through polypharmacology Nat. Rev. Cancer 2010, 10, 130-137
82. Fedorov, O.; Müller, S.; Knapp, S. The (un)target cancer kinome Nat. Chem. Biol. 2010, 6, 166-169
83. Gossage, L.; Eisen, T. Targeting multiple kinase pathways: a change in paradigm Clin. Cancer Res. 2010, 16, 1973-1978
84. 13C NMR spectroscopy of oleanane triterpenoids Prog. NMR Spectrosc. 1992, 24, 1-90
85. 13C NMR spectra of pentacyclic triterpenoids - a compilation and some salient features Phytochemistry 1994, 37 (6) 1517-1575
86. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision Glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196 (Pubitemid 44595196)
87. Arrigo, A. P.; Tanaka, K.; Goldberg, A. L.; Welch, W. J. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome) Nature (London) 1988, 331, 192-194 (Pubitemid 18042153)
88. Sadowski, J. A hybrid approach for addressing ring flexibility in 3D database searching J. Comput.-Aided Mol. Des. 1997, 11, 53-60 (Pubitemid 127505890)
89. Moravec, R. A.; O'Brien, M. A.; Daily, W. J.; Scurria, M. A.; Bernad, L.; Riss, T. L. Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format Anal. Biochem. 2009, 387, 294-302
90. Lamoral-Theys, D.; Pottier, L.; Kerff, F.; Dufrasne, F.; Proutière, F.; Wauthoz, N.; Neven, P.; Ingrassia, L.; Van Antwerpen, P.; Lefranc, F.; Gelbcke, M.; Pirotte, B.; Kraus, J. L.; Nève, J.; Kornienko, A.; Kiss, R.; Dubois, J. Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli Bioorg. Med. Chem. 2010, 18, 3823-3833